Clinical Trial Update: Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating rosiglitazone and alpha-lipoic acid in pathologically proven non-alcoholic steatohepatitis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Steatohepatitis

Drugs mentioned

• Alpha Lipoic Acid (alpha-lipoic acid)
• Rosiglitazone (rosiglitazone)

Snippet

Sponsor: Seoul St. Mary's Hospital | Conditions: NASH (Non-alcoholic Steato-hepatitis) | Phase 4 | Status: TERMINATED